Topic: epidermal growth factor receptor (EGFR)
AZ already has a Tagrisso nod for patients with previously untreated, EGFR-mutated lung cancer. But it’s shoring up its case with clutch new data.
England’s cost watchdogs won’t get behind AZ blockbuster Tagrisso. But in a change of events, they’re instead backing a Pfizer challenger.
AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.
Eli Lilly has new data that could help expand Cyramza’s lung cancer footprint, but a tough marketing battle awaits.
Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.
It’s been a long road for Pfizer’s dacomitinib, but the targeted lung cancer drug finally has an FDA green light.
Tagrisso will enjoy quick uptake in a couple of new indications to win 95% of EGFR-mutated NSCLC patients by 2020, a bullish analyst figures.
The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.